MaxCyte To Be Sponsor and Featured Speaker at the Phacilitate Cell and Gene Therapy Forum 2006
Posted on: Wednesday, 25 January 2006, 09:01 CST
GAITHERSBURG, Md., Jan. 25 /PRNewswire/ -- MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announces Madhusudan V. Peshwa, Ph.D., Vice President Research and Development, will be speaking at the Phacilitate Cell and Gene Therapy Forum in Baltimore, Maryland, on Monday, January 30, 2006, at 3:05 PM. Dr. Peshwa's presentation entitled "Overcoming the technical and regulatory hurdles in the preclinical to clinical transition for cellular therapeutics," will discuss the application of a robust, scaleable, GMP compliant, closed system for non- viral gene delivery in the clinical development of an engineered tumor vaccine product for treatment of B-cell Chronic Lymphocytic Leukemia.
About MaxCyte
MaxCyte, Inc. is a clinical stage company developing cell-based therapeutics primarily in the areas of oncology and regenerative medicine. MaxCyte's pipeline includes one product in Phase I/II clinical trials for the treatment of Chronic Lymphocytic Leukemia (CLL) and several preclinical candidates to treat a variety of diseases with unmet needs. The company also offers its unparalleled, customizable flow based cell loading technology to partners who take advantage of its advanced capabilities for cell-based therapeutic development and biotherapeutic (viral vector) manufacturing through licensing relationships. Partners are currently working to develop therapeutics for pulmonary, cardiovascular and infectious disease, cancer and regenerative medicine.
For more information, visit http://www.maxcyte.com/.
This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.
First Call Analyst: FCMN Contact:
MaxCyte, Inc.
CONTACT: Anthony Recupero, Ph.D., Vice President, Business Development ofMaxCyte, Inc., +1-301-944-1700
Web site: http://www.maxcyte.com/
Source: PRNewswire
Related Articles
- Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators
- Koronis Pharmaceuticals Announces Appointment of Prominent HIV Researcher Courtney Fletcher, Pharm. D., To Scientific Advisory Board and Jeff Parkins As VP, Clinical Development
- ImmunoCellular Therapeutics Elects Dr. James Bender to Position of Vice President, Clinical Development
- Medinet Starts Commercialization of Novel Cancer Immunotherapy Technology in Japan Utilizing MaxCyte's Cell Loading System
- Cytheris Receives EUR 1.5 Million ($2.3 Million) From OSEO for HCV Clinical Development Program
- Repros Therapeutics Inc. Reports First Quarter 2008 Financial Results and Provides Clinical Development Program Overview
- Phase II Results for CDP791 in Non-Small Cell Lung Cancer Support Further Clinical Development
- Repros Therapeutics Inc. Reports Fourth Quarter and Year End 2007 Financial Results and Provides Clinical Development Program Overview
- Synvista Therapeutics Appoints Carl M. Mendel, M.D. Vice President, Clinical Development and Chief Medical Officer
- Viron Therapeutics Appoints Claude Benedict, M.D. As New Senior Vice President, Clinical Development and Regulatory Affairs
 |
 |
User Comments (0)
RSS Feeds